Seres Therapeutics Ditches Its SER-301 Phase 1b Second Study In Ulcerative Colitis
- In its SEC filing, Seres Therapeutics Inc (NASDAQ: MCRB) disclosed it would not move forward with the planned SER-301 Phase 1b second study cohort.
- In its Q4 earnings release, Seres said that SER-301 was safe to proceed to the placebo-controlled second cohort in a Phase Ib trial even though outcome data from the 15 patients indicated none of them had achieved clinical remission after 10 weeks of treatment.
- The Company plans to continue research activities evaluating ulcerative colitis based on SER-287 and SER-301 trial data.
- "Clinical data suggest the potential for biomarker-based patient selection," Seres revealed in the presentation.
- In March, the Company said SER-301 led to improvements in endoscopic, stool frequency, and rectal bleeding sub-scores for some patients.
- Seres plots for a mid-year approval request for its C. difficile therapeutic, SER-109.
- Related: Seres Therapeutics' Oral Microbiome Candidate Shows Meaningful Improvements In Difficile Infection.
- In a Phase 2b study last year, Seres said SER-287 did not improve clinical remission rates compared to placebo.
- Price Action: MCRB shares are down 0.69% at $7.21 during the market session on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs Phase 1 Trial ulcerative colitisBiotech News Health Care Small Cap General
